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Dear editor, 51 
 52 
Organosilicon compounds are efflux pump inhibitors with potency as an antituberculosis 53 
drug. Of the organisilicon compounds tested, SILA 421 has been shown to have a highest 54 
potency as an antituberculosis drug (1). It shares the common pathways for antimycobacterial 55 
killing with other efflux pump inhibitors: it revealed direct in vitro activity against M. 56 
tuberculosis (1), it has been shown to modify resistance by inhibiting mdr-1 efflux pumps and 57 
has shown to enhance killing of M. tuberculosis by macrophages (1). However, the activity of 58 
SILA 421 has only been tested against the M. tuberculosis H37Rv type strain and one clinical 59 
XDR M. tuberculosis isolate so far (1). We therefore assessed the antimycobacterial activity 60 
of SILA 421 against an extended set of M. tuberculosis strains with varying drug 61 
susceptibility profiles. Secondly, we compared antimycobacterial activity of SILA 421 with 62 
that of thioridazine and other phenothiazines.  63 
We selected 21 clinical M. tuberculosis isolates with varying drug susceptibility profiles: five 64 
isolates were pansusceptible, 11 were monoresistant (6 isoniazid monoresistant, 4 rifampin 65 
monoresistant and 1 streptomycin monoresistant) and 5 were MDR M. tuberculosis isolates. 66 
All isolates were extracted from a -70 °C freezer collection and sub-cultured on Ogawa 67 
medium. Inoculum preparation was performed as described previously aiming at 2 x 103 to 10 68 
x 103 CFU (2). To determine the Minimal Inhibitory Concentration (MIC) we performed 69 
drug-susceptibility testing using a well-standardized Middlebrook 7H10 agar dilution method 70 
as described previously (2) using the following drug concentrations: 1, 2, 4, 8, and 16 mg/L. 71 
All drugs were received as chemically pure powder. SILA 421 was provided by Dr. G. Hajos 72 
(Institute for Biomolecular Chemistry, Budapest, Hungary). Chlorpromazine, desipramine, 73 
promazine and thioridazine were obtained from Sigma-Aldrich (Zwijndrecht, the 74 
Netherlands). Because the thioridazine S-enantiomer might induce less side-effects (4) we 75 
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studied both thioridazine enantiomers separately. The two thioridazine enantiomers were 76 
prepared by Dr. J.B. Christensen (Dept. Chemistry, Copenhagen, Denmark). All drugs were 77 
dissolved in distilled water to a stock solution of 10 g/L 78 
The MIC of SILA 421 could be determined after a median of 14 days (range 14-18 days). The 79 
MIC50 was 4 mg/L and the MIC90 was 8 mg/L. Table 1 shows the comparison of the MIC50 80 
and MIC90 of SILA 421 with the various phenothiazines. The MICs found for the 81 
phenothiazines were comparable with those found in the literature (3).  The MIC50 of SILA 82 
421 was similar to the MIC50 of thioridazine and chlorpromazine. On the contrary, MIC50 of 83 
both desipramine and promazine were both much higher than the MIC50 of SILA 421. When 84 
comparing the MIC90, lowest MIC90 was measured for SILA 421. 85 
These data show that the SILA 421 is active in vitro against M. tuberculosis isolates with a 86 
wide variety of drug susceptibility patterns, thereby providing incremental evidence of its 87 
antimycobacterial activity. Moreover, we showed that SILA 421 is equally active in vitro as 88 
thioridazine, another well-known efflux pump inhibitor.   89 
In a previous study, SILA 421 has been proposed to be more potent that thioridazine (1). 90 
However, only two M. tuberculosis isolates had been tested (1). The present study confirms 91 
that SILA 421 may be a promising antituberculosis drug with activity against a wide variety 92 
of M. tuberculosis strains comparable to that of thioridazine. Further studies are warranted to 93 
investigate the potency of SILA 421 as an antituberculosis drug in animals and in humans. 94 
Besides its antimycobacterial activity, SILA 421 might also have another appealing feature. 95 
Like all efflux pump inhibitors, SILA 421 will inhibit the activity of efflux pumps of MDR 96 
mycobacteria, presumptively rendering mycobacteria more susceptible to the antituberculosis 97 
drugs to which it was initially resistant as a consequence of their extrusion from the cell (5). 98 
Thus, these drug resistance modifiers might be of interest not only for their immediate 99 
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antimycobacterial activity but also as an adjunctive agent to be added to new or existing 100 
antituberculosis regimens.  101 
Of additional interest is our finding that the S-enantiomer of thioridazine is as effective as 102 
thioridazine itself against M. tuberculosis. It is thought this S-enantiomer might induce less 103 
neurological side effects owing to a lower affinity to the D2 dopamine receptor (4), putatively 104 
favoring the S-enantiomer over the racemate as an antituberculosis drug. However, it is 105 
unknown if the D2 dopamine receptor is the only target for neurological side-effects of 106 
thioridazine and it is unclear whether the pharmacokinetic and pharmacodynamic properties 107 
of the thioridazine enantiomers are equal. Notwithstanding these limitations, our findings 108 
raise hope that structural optimization of thioridazine-derivatives is possible without losing 109 
antimycobacterial activity (3.4).  110 
In conclusion, the present study provides confirmatory and incremental evidence of the 111 
antimycobacterial activity of SILA 421 and the phenothiazines, such as thioridazine. 112 
Therapeutic opportunities lay in the structural optimization of these drugs as well as in their 113 
drug resistance modifying effect. Future studies should bring SILA 421 and the 114 
phenothiazines further up the drug development pipeline.115 
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Table 1  142 
The MIC50 and MIC90 of SILA 421 and the various phenothiazines(a). 143 
Efflux pump inhibitor MIC50 (mg/L) MIC90 (mg/L) Range (mg/L) 
SILA 421 4 8 2 - 16 
Thioridazine 4 16 2 - 16 
Thioridazine, S-enantiomer 8 16 4 - 16 
Thioridazine, R-enantiomer 8 16 4 - 16 
Chlorpromazine 4 16 <1 - 16 
Desipramine(b) >16 >16 16 - >16 
Promazine(b) >16 >16 16 - >16 
(a) MIC50, MIC at which ≥ 50% of isolates are inhibited. MIC90, MIC at which ≥ 90% of 144 
isolates are inhibited. 145 
(b) MIC distribution was based on 20 instead of 21 isolates. 146 
 147 
